Table 1.
Baseline Characteristics
| Characteristic | Overall | AF Cohort | Non‐AF Cohort | P Value* |
|---|---|---|---|---|
| Number of subjects | 160 456 | 23 807 | 136 649 | |
| Age, y | ||||
| Mean, SD | 69 (±14.8) | 77 (±11.6) | 67 (±14.8) | <0.0001 |
| Age group | ||||
| <55, N (%) | 29 572 (18.4) | 1048 (4.4) | 28 560 (20.9) | |
| 55 to 64, N (%) | 39 376 (24.6) | 3285 (13.8) | 36 075 (26.4) | |
| 65+, N (%) | 91 508 (57.0) | 19 474 (81.8) | 72 014 (52.7) | |
| Female, % | 51.5 | 50.7 | 51.6 | 0.0121 |
| Geographic Region, % | ||||
| Northeast | 12.8 | 15.3 | 12.4 | <0.0001 |
| North Central | 34.6 | 35.3 | 34.4 | |
| West | 17.1 | 19.7 | 16.7 | |
| South | 35.3 | 29.5 | 36.3 | |
| Unknown | 0.2 | 0.3 | 0.2 | |
| Metropolitan statistical area, % | 84.0 | 84.0 | 82.9 | <0.0001 |
| Stroke Type, % | ||||
| Ischemic | 49.9 | 59.9 | 48.2 | <0.0001 |
| TIA | 36.2 | 27.3 | 37.8 | |
| Hemorrhagic | 13.9 | 12.8 | 14.1 | |
| Type of Hemorrhagic Stroke*, % | ||||
| Subarachnoid | 25.3 | 8.9 | 27.9 | |
| Intracerebral | 51.2 | 58.4 | 50.0 | |
| Other and unspecified intracranial | 23.5 | 32.6 | 22.0 | |
| Selected Comorbidities (>5% frequency, %) | ||||
| Chronic obstructive pulmonary disease | 9.7 | 15.0 | 8.8 | <0.0001 |
| Congestive heart failure (excluding left ventricular) | 9.0 | 24.1 | 6.4 | <0.0001 |
| Diabetes mellitus | 24.6 | 26.9 | 24.2 | <0.0001 |
| Hypertension | 51.2 | 62.1 | 49.3 | <0.0001 |
| Malignancy | 13.9 | 19.1 | 13.0 | <0.0001 |
| Peripheral vascular disease | 9.6 | 15.2 | 8.6 | <0.0001 |
| OAC use, % | 10.2 | 43.5 | 4.4 | <0.0001 |
AF indicates atrial fibrillation; OAC, oral anticoagulant; TIA, transient ischemic attack; SD, standard deviation.
*
Fisher's exact or Wilcoxon test.
*
Type of hemorrhagic stroke was not tested.
Source: Truven MarketScan® Research Databases January 1, 2005 to December 31, 2011.